BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
Author:
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology
Reference77 articles.
1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood.,2013
2. Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents;Talati;Curr Opin Hematol.,2018
3. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies;Lovly;Clin Cancer Res.,2014
4. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro;Eadie;Oncotarget.,2018
5. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib;Dohse;Drug Metab Dispos.,2010
Cited by 82 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels;Medical Oncology;2024-01-12
2. Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia;Pathology and Oncology Research;2023-12-22
3. Literature Review of Hematology Division The Mechanism of Imanitib Resistance in Chronic Myeloid Leukemia;Research Journal of Pharmacy and Technology;2023-11-30
4. Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis;Leukemia;2023-10-17
5. Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells;Hematology;2023-08-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3